WARRINGTON, Pa., Aug. 3, 2015 /PRNewswire/ -- Discovery
Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology
company focused on developing aerosolized KL4 surfactant therapies
for respiratory diseases, will host a live teleconference and
webcast at 8:30 a.m. Eastern Time on Tuesday August 11, 2015 at which time management
will discuss the 2015 second quarter financial results along with
providing other business updates. The company will issue a press
release announcing the second quarter 2015 financial results after
the close of the U.S. financial markets on Monday, August 10, 2015.
The press release and the live webcast of the conference call
will be available via Discovery Labs' corporate website at
www.discoverylabs.com. The webcast will be made available on
the events page. An archive will be available after the call
at the same address.
To participate in the live conference call, please dial (888)
346-0767 (domestic) or (412) 902-4251 (international). After
placing the call, please ask to be joined into the Discovery Labs
conference call. The conference call replay number is (877)
344-7529 (domestic) or (412) 317-0088 (international); please use
10070663 as the replay passcode.
About Discovery Labs
Discovery Laboratories, Inc. is
a specialty biotechnology company focused on developing aerosolized
KL4 surfactant therapies for respiratory diseases. Pulmonary
surfactants are produced naturally in the lung and are essential
for normal respiratory function and survival. If surfactant
deficiency or degradation occurs, the air sacs in the lungs can
collapse, resulting in severe respiratory diseases and
disorders. Discovery Labs' technology platform includes a
novel synthetic peptide-containing (KL4) surfactant that is
structurally similar to naturally occurring pulmonary surfactant
and proprietary drug delivery technologies being developed to
enable efficient delivery of aerosolized KL4 surfactant.
Discovery Labs believes that its proprietary technology platform
makes it possible, for the first time, to develop a significant
pipeline of aerosolized surfactant products to address a variety of
respiratory diseases for which there frequently are few or no
approved therapies.
For more information, please visit the company's website at
www.Discoverylabs.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/discovery-labs-to-hold-conference-call-on-tuesday-august-11-2015-to-discuss-second-quarter-2015-financial-results-and-other-business-updates-300122614.html
SOURCE Discovery Laboratories, Inc.
